Advancing mRNA-based Antiviral Therapy

The NoVir team has gathered for the first time to meet face-to-face since the project has launched in May 2025. On November 27-28, the partners met on the premises of the coordinating institution Ethris in Planegg near Munich, Germany to discuss recent scientific progress and strategic developments across key work packages.

Kicking off with a scientific workshop, the Ethris team presented the latest results from the Phase I clinical study of ETH47, a first-in-class mRNA-based antiviral therapy, providing an in-depth overview of safety and early efficacy data. A subsequent session focused on progress and next steps in the two Phase II proof-of-concept clinical trials. In addition, researchers from Technical University of Munich and Aarhus University shared significant findings from their studies on the effect of ETH47 on virus replication in vitro and ex vivo, offering valuable insights into therapeutic potential and remaining challenges.

The scientific discussion was complemented by updates on project management, outreach and exploitation activities covering topics such as risk assessment and monitoring, as well as plans to strengthen the collaboration with related European projects alongside capacity-building and exploitation efforts.

The meeting was rounded off by a tour of the Ethris lab offering insights into the research environment and technological capabilities driving the project's clinical work forward.